Identification of B-cell lymphoma subsets by plasma protein profiling using recombinant antibody microarrays

Frida Pauly; Karin E Smedby; Mats Jerkeman; Henrik Hjalgrim; Mattias Ohlsson; Richard Rosenquist; Carl A K Borrebaeck; Christer Wingren

doi:10.1016/j.leukres.2014.03.010

Identification of B-cell lymphoma subsets by plasma protein profiling using recombinant antibody microarrays

Leuk Res. 2014 Jun;38(6):682-90. doi: 10.1016/j.leukres.2014.03.010. Epub 2014 Mar 22.

Authors

Frida Pauly¹, Karin E Smedby², Mats Jerkeman³, Henrik Hjalgrim⁴, Mattias Ohlsson⁵, Richard Rosenquist⁶, Carl A K Borrebaeck¹, Christer Wingren⁷

Affiliations

¹ Department of Immunotechnology, Lund University, Lund, Sweden; CREATE Health, Lund University, Lund, Sweden.
² Department of Medicine Solna, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden.
³ Department of Oncology, Skåne University Hospital, Lund, Sweden.
⁴ Department of Epidemiology Research, Statens Serum Institute, Copenhagen, Denmark.
⁵ Computational Biology & Biological Physics, Department of Astronomy and Theoretical Physics, Lund University, Lund, Sweden; CREATE Health, Lund University, Lund, Sweden.
⁶ Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
⁷ Department of Immunotechnology, Lund University, Lund, Sweden; CREATE Health, Lund University, Lund, Sweden. Electronic address: christer.wingren@immun.lth.se.

PMID: 24754901
DOI: 10.1016/j.leukres.2014.03.010

Abstract

B-cell lymphoma (BCL) heterogeneity represents a key issue, often making the classification and clinical management of these patients challenging. In this pilot study, we outlined the first resolved view of BCL disease heterogeneity on the protein level by deciphering disease-associated plasma biomarkers, specific for chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma, using recombinant antibody microarrays targeting mainly immunoregulatory proteins. The results showed the BCLs to be heterogeneous, and revealed potential novel subgroups of each BCL. In the case of diffuse large B-cell lymphoma, we also indicated a link between the novel subgroups and survival.

Keywords: B-cell lymphoma; Biomarker; CLL; DLBCL; Disease heterogeneity; FL; MCL; Plasma protein profiling.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antibodies / immunology
Blood Proteins / analysis*
Female
Humans
Lymphoma, B-Cell / blood
Lymphoma, B-Cell / classification*
Male
Middle Aged
Pilot Projects
Protein Array Analysis / methods*
Proteome
Recombinant Proteins / immunology

Substances

Antibodies
Blood Proteins
Proteome
Recombinant Proteins